Radiopharm Theranostics Limited (ASX:RAD)
Australia flag Australia · Delayed Price · Currency is AUD
0.0240
-0.0010 (-4.17%)
Aug 7, 2025, 4:10 PM AEST

Radiopharm Theranostics Company Description

Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs.

It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast cancer and other solid tumors; and RAD 301, a diagnostic radiopharmaceutical targeting αvβ6 integrin in pancreatic ductal adenocarcinoma patients.

The company also develops RAD 302, an αvβ6-integrin targeting agent for the treatment of multiple cancer types; RAD 101 and RAD 102 for brain metastases; RAD 402 to treat advanced prostate cancer; and RV01 for multiple solid tumors.

It has strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals.

The company was incorporated in 2021 and is based in Carlton, Australia.

Radiopharm Theranostics Limited
CountryAustralia
Founded2021
IndustryBiotechnology
SectorHealthcare
CEORiccardo Canevari

Contact Details

Address:
62 Lygon Street
Carlton, 3053
Australia
Phone61 3 9824 5254
Websiteradiopharmtheranostics.com

Stock Details

Ticker SymbolRAD
ExchangeAustralian Securities Exchange
Fiscal YearJuly - June
Reporting CurrencyAUD
ISIN NumberAU0000181851
SIC Code2834

Key Executives

NamePosition
Riccardo CanevariMD, Chief Executive Officer and Director
Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICDFounder and Executive Chairman
Phillip HainsChief Financial Officer, Joint Company Secretary and Director
Dr. Dimitris Voliotis M.D.Chief Medical Officer
Hitesh GoelHead of Project Management
Nathan Jong C.A.Joint Company Secretary